Records containing: Metastatic Triple-Negative Breast Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-27"A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study
-
CLINICAL_TRIALS study record update · 2026-04-22ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
-
CLINICAL_TRIALS study record update · 2026-04-17"A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study
-
CLINICAL_TRIALS study record update · 2026-04-16Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
-
CLINICAL_TRIALS study record update · 2025-12-30A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-03-25A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
-
CLINICAL_TRIALS study record update · 2022-01-10Anrotinib in Combination With Capecitabine in the Single-arm, Open Phase II Treatment of Relapsed or Metastatic Triple-negative Breast Cancer Clinical Research
-
CLINICAL_TRIALS study record update · 2021-05-19Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile